Jefferies Group set a $90.00 price target on Eli Lilly and (NYSE:LLY) in a report issued on Friday morning. The brokerage currently has a buy rating on the stock. Jefferies Group also issued estimates for Eli Lilly and’s Q1 2018 earnings at $1.11 EPS, FY2019 earnings at $5.26 EPS, FY2020 earnings at $6.13 EPS and FY2022 earnings at $7.77 EPS.
Several other equities research analysts have also recently weighed in on LLY. Argus raised Eli Lilly and from a hold rating to a buy rating and increased their price target for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Goldman Sachs cut Eli Lilly and from a buy rating to a neutral rating and increased their price target for the company from $86.98 to $95.00 in a research note on Tuesday, January 16th. Credit Suisse Group cut Eli Lilly and from a neutral rating to an underperform rating and set a $82.00 target price for the company. in a research note on Monday, January 22nd. BMO Capital Markets raised their target price on Eli Lilly and from $73.00 to $74.00 and gave the stock an underperform rating in a research note on Thursday, February 1st. Finally, Bank of America decreased their target price on Eli Lilly and from $88.00 to $86.00 and set a neutral rating for the company in a research note on Thursday, February 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $93.16.
Shares of LLY stock opened at $80.12 on Friday. The stock has a market capitalization of $87,341.06, a PE ratio of 18.72, a P/E/G ratio of 1.49 and a beta of 0.26. The company has a quick ratio of 1.01, a current ratio of 1.32 and a debt-to-equity ratio of 0.85. Eli Lilly and has a 1-year low of $73.69 and a 1-year high of $89.09.
In related news, CFO Joshua L. Smiley sold 3,000 shares of Eli Lilly and stock in a transaction on Friday, March 16th. The stock was sold at an average price of $79.20, for a total transaction of $237,600.00. Following the sale, the chief financial officer now directly owns 20,029 shares in the company, valued at $1,586,296.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of Eli Lilly and stock in a transaction on Monday, February 5th. The stock was sold at an average price of $81.12, for a total value of $780,780.00. Following the sale, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold 15,261 shares of company stock worth $1,225,085 in the last 90 days. Corporate insiders own 0.11% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Eli Lilly and by 1.2% during the fourth quarter. BlackRock Inc. now owns 63,854,112 shares of the company’s stock worth $5,393,119,000 after acquiring an additional 776,893 shares during the period. Franklin Resources Inc. increased its position in Eli Lilly and by 2.7% in the fourth quarter. Franklin Resources Inc. now owns 28,519,524 shares of the company’s stock worth $2,408,787,000 after buying an additional 754,681 shares during the last quarter. Janus Henderson Group PLC increased its position in Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after buying an additional 1,503,918 shares during the last quarter. Geode Capital Management LLC increased its position in Eli Lilly and by 4.3% in the fourth quarter. Geode Capital Management LLC now owns 9,854,964 shares of the company’s stock worth $830,522,000 after buying an additional 406,812 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in Eli Lilly and by 1.8% in the fourth quarter. UBS Asset Management Americas Inc. now owns 6,636,386 shares of the company’s stock worth $560,509,000 after buying an additional 115,499 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.